Items Tagged ‘osimertinib’

December 19th, 2016

Tagrisso®: New Standard of Care for Certain Lung Cancer

By

Treatment with the targeted agent Tagrisso (osimertinib) significantly delayed cancer progression, and resulted in fewer side effects, than standard chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) whose cancer had progressed following prior therapy with an epidermal growth factor receptor (EGFR) inhibitor. Lung cancer remains the leading cause of cancer-related deaths in the […]

View full entry

Tags: EGFR, epidermal growth factor receptor, General Lung Cancer, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, osimertinib, Stages IIIB-IV Lung Cancer - Non-Small Cell, T790 mutation, tagrisso


November 19th, 2015

Novel Precision Medicine Tagrisso Approved for Treatment of Lung Cancer

By

The United States Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for the treatment of lung cancer with the epidermal growth factor receptor (EGFR) T790M mutation. The indication specifies that patients must have non-small cell lung cancer (NSCLC) that has progressed despite treatment with other approved agents that block the EGFR pathway. The diagnostic […]

View full entry

Tags: Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, osimertinib, T790M mutation, tagrisso